Drug Type Small molecule drug |
Synonyms Aclacinomycin A, Aclarubicin, Aclarubicin Hydrochlorid + [9] |
Target |
Mechanism DNA inhibitors(DNA inhibitors), Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (04 Jun 1981), |
Regulation- |
Molecular FormulaC42H54ClNO15 |
InChIKeyKUSMIBXCRZTVML-PCCPLWKKSA-N |
CAS Registry75443-99-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Aclarubicin Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Breast Cancer | JP | 04 Dec 1981 | |
Leukemia | JP | 04 Jun 1981 | |
Lung Cancer | JP | 04 Jun 1981 | |
Lymphoma | JP | 04 Jun 1981 | |
Ovarian Cancer | JP | 04 Jun 1981 | |
Stomach Cancer | JP | 04 Jun 1981 |
NCT05662956 (EHA2024) Manual | Phase 2 | Acute Myeloid Leukemia First line | Induction | 67 | worwnnrxyo(czycnxzyrv) = gjqfindskp hwdgdkyxur (gshzkbgqnz ) View more | Positive | 14 May 2024 | |
Not Applicable | 43 | IAG group | pskenqagua(urregdqlmz) = ixzhaucnwr eqdsonmsco (liqaqfwjms ) View more | - | 21 May 2015 | ||
CAG group | pskenqagua(urregdqlmz) = lptrnorgyn eqdsonmsco (liqaqfwjms ) View more |